Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus
Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus
About this item
Full title
Author / Creator
Publisher
United States: The University of Chicago Press
Journal title
Language
English
Formats
Publication information
Publisher
United States: The University of Chicago Press
Subjects
More information
Scope and Contents
Contents
Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus (RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children. Ribavirin is approved for treatment of severe RSV disease; however, its effectiveness in improving outcomes is questionable. During the past 40 years, many obstacles...
Alternative Titles
Full title
Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2851489
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2851489
Other Identifiers
ISSN
1058-4838
E-ISSN
1537-6591
DOI
10.1086/651603
